Real-time fMRI Neurofeedback in Patients With MCI

NCT04020744 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2024-05-08

No results posted yet for this study

Summary

Increased activity in the hippocampus (i.e., hyperactivity) during a fMRI memory task was found in patients with Mild Cognitive Impairment due to Alzheimer's disease (MCI). Those with increased hippocampal activity exhibited elevated clinical progression. Reducing hippocampal hyperactivity with pharmacological treatment reduced hyperactivity and improved memory performance. The investigators of this study will test whether real-time fMRI neurofeedback will also downregulate hippocampal activity and thereby improve memory performance.

Conditions

Interventions

OTHER

real-time fMRI based neurofeedback from the hippocampus

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

OTHER

real-time fMRI based neurofeedback from another brain area

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER
  • University of Bern

    lead OTHER

Principal Investigators

  • Jessica Peter, PD Dr. · University of Bern

  • Stefan Klöppel, Prof. Dr. · University of Bern

  • Frank Scharnowski, Prof. Dr. · University of Vienna

  • Roland Wiest, Prof. Dr. · University of Bern

  • Katharina Klink · University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2023-10-31
Completion
2024-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04020744 on ClinicalTrials.gov